AI confidence 70% · prior close shown (market closed)
Investment Snapshot
Why it matters
AGILENT TECHNOLOGIES, INC. shows decelerating business momentum based on AlphaOS pipeline evidence.
Why it matters: Revenue +8% YoY in Q3 FY2026.
1 signal not yet derived from pipeline evidence
Key signals
What it means for the thesis — synthesis, not a raw event feed.
- Revenue +8% YoY in Q3 FY2026
- Revenue Deceleration Severe
Pipeline evidence · 0d ago
A's AlphaOS Signals
Upgrade to Pro for validated historical pattern analysis on A.
Free accounts see more of this; Premium sees all of it.
Latest earnings · Q3 2026
Full A earnings analysisReported figures for AGILENT TECHNOLOGIES, INC. — research only, not investment advice.
- Revenue YoY
- +8.0%
- EPS YoY
- +8.5%
Latest Intelligence
Updated
What happened recently for AGILENT TECHNOLOGIES, INC. (A) — events, not interpretation.
- Event
- Reported Q3 2026 revenue +8% YoY.
- Also
- Last session September 28, 2026 at $175.21.
- Source
- Q3 2026 earnings
Research & analysis only — not investment advice.
Building company intelligence…
AGILENT TECHNOLOGIES, INC. (A)
Investment Snapshot above is the primary AlphaOS analysis for AGILENT TECHNOLOGIES, INC. — structured signals and evidence from proprietary pipelines, not an encyclopedia overview.
Key facts
- Sector:
- Healthcare
- Industry:
- Diagnostics & Research
- Market cap:
- $49.40B
- Revenue:
- $1.88B
Research & analysis only — not investment advice. Price, charts, and filings are above.
Connected intelligence
Follow AGILENT TECHNOLOGIES, INC. through AlphaOS's knowledge graph — themes, peers, beneficiaries, earnings, and research answers.
AGILENT TECHNOLOGIES, INC. (A) in AlphaOS research
- theme
Genomics & Biotech: Precision Medicine Is Rewriting Drug Development
The shift from broad-spectrum drugs to gene-level targeting is concentrating value in a surprisingly narrow set of platform companies.
- theme
Healthcare Innovation: Where the Real Edge Lives
The biggest gains aren't in blockbuster drugs — they're in the infrastructure that makes every drug possible.
- theme
Genomics & Biotech: Precision Medicine Is Reshaping Drug Development
The tools to read, edit, and deliver on the genome are maturing faster than the market prices in.
- theme
Healthcare Innovation: Precision Beats Volume
The edge in healthcare no longer belongs to the biggest drug pipelines — it belongs to the most targeted ones.
- theme
Genomics & Biotech: Precision Medicine Hits an Inflection Point
Gene editing and mRNA platforms are moving from research curiosity to approved therapies faster than the market expected.
- theme
Genomics & Biotech: Advancing Precision Medicine
Breakthroughs in gene editing and targeted therapies are reshaping healthcare landscapes.
Related & Connected
Related stock research
Connected companies and research pages from the AlphaOS knowledge graph.
- CYBIN INC. (HELP)Investment Snapshot & knowledge graph →
- INNODATA INC (INOD)Investment Snapshot & knowledge graph →
- Palo Alto Networks Inc (PANW)Investment Snapshot & knowledge graph →
- OLD DOMINION FREIGHT LINE, INC. (ODFL)Investment Snapshot & knowledge graph →
- APPLIED MATERIALS INC /DE (AMAT)Investment Snapshot & knowledge graph →
- AXT INC (AXTI)Investment Snapshot & knowledge graph →
Related stock research
Structured stock intelligence for companies connected to this research.